Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab
Rhona Stein(Center for Molecular Medicine and Immunology), David M. Goldenberg(Immunomedics (United States))
Cited by 54
Related Papers
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
|Oncotarget|2015|464
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
|Oncotarget|2018|306
Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers
|BMC Cancer|2007|273
Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement
|British Journal of Cancer|2010|52